Literature DB >> 10679919

A sporadic breast tumor with a somatically acquired complex genomic rearrangement in BRCA1.

M van der Looij1, A M Cleton-Jansen, R van Eijk, H Morreau, M van Vliet, N Kuipers-Dijkshoorn, E Oláh, C J Cornelisse, P Devilee.   

Abstract

Germ-line mutations in BRCA1 cause a substantial proportion of inherited breast cancer, and most result in inactivated BRCA1 proteins upon translation. Tumours developing in BRCA1 mutation carriers generally show loss of the wild-type allele. However, acquired inactivating mutations in BRCA1 in non-inherited breast tumours showing loss of heterozygosity at the gene locus have not been detected so far. Here we provide evidence that such mutations can be detected in a small proportion of breast tumours. Prompted by recent reports of Alu-mediated large genomic rearrangements in BRCA1, we have investigated whether such rearrangements might occur in sporadic breast cancer as well and have been missed thus far by traditional PCR-based mutation screening technology. To this end, we performed Southern blot analysis of 81 apparently sporadic breast tumours using probes covering exons 6-24 and 3 restriction enzymes. We identified 1 case with an acquired rearrangement (1.2%), indicating that BRCA1 inactivation through changes in the primary genomic sequence of the gene is uncommon in breast cancer. Genes Chromosomes Cancer 27:295-302, 2000. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10679919     DOI: 10.1002/(sici)1098-2264(200003)27:3<295::aid-gcc10>3.0.co;2-f

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  9 in total

Review 1.  Emerging roles of BRCA1 alternative splicing.

Authors:  T I Orban; E Olah
Journal:  Mol Pathol       Date:  2003-08

2.  Loss of heterozygosity of the BRCA1 and FHIT genes in patients with sporadic breast cancer from Southern Brazil.

Authors:  S C L Santos; L R Cavalli; I J Cavalli; R S Lima; B R Haddad; E M S F Ribeiro
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

3.  Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.

Authors:  Robert M W Hofstra; Amanda B Spurdle; Diana Eccles; William D Foulkes; Niels de Wind; Nicoline Hoogerbrugge; Frans B L Hogervorst
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

4.  Decreased expression of BRCA1 in SK-BR-3 cells is the result of aberrant activation of the GABP Beta promoter by an NRF-1-containing complex.

Authors:  Crista Thompson; Gwen MacDonald; Christopher R Mueller
Journal:  Mol Cancer       Date:  2011-05-24       Impact factor: 27.401

5.  BRCA1 Alternative splicing landscape in breast tissue samples.

Authors:  Atocha Romero; Francisco García-García; Irene López-Perolio; Gorka Ruiz de Garibay; José A García-Sáenz; Pilar Garre; Patricia Ayllón; Esperanza Benito; Joaquín Dopazo; Eduardo Díaz-Rubio; Trinidad Caldés; Miguel de la Hoya
Journal:  BMC Cancer       Date:  2015-04-03       Impact factor: 4.430

6.  Prevalence of deleterious mutations among patients with breast cancer referred for multigene panel testing in a Romanian population.

Authors:  Iulian Gabriel Goidescu; Gabriela Caracostea; Dan Tudor Eniu; Florin Vasile Stamatian
Journal:  Clujul Med       Date:  2018-04-25

7.  Characterization of a negative transcriptional element in the BRCA1 promoter.

Authors:  Gwen MacDonald; Melissa Stramwasser; Christopher R Mueller
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

Review 8.  Regulation of BRCA1 expression and its relationship to sporadic breast cancer.

Authors:  Christopher R Mueller; Calvin D Roskelley
Journal:  Breast Cancer Res       Date:  2002-11-13       Impact factor: 6.466

9.  Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic.

Authors:  C Winter; M P Nilsson; E Olsson; A M George; Y Chen; A Kvist; T Törngren; J Vallon-Christersson; C Hegardt; J Häkkinen; G Jönsson; D Grabau; M Malmberg; U Kristoffersson; M Rehn; S K Gruvberger-Saal; C Larsson; Å Borg; N Loman; L H Saal
Journal:  Ann Oncol       Date:  2016-05-18       Impact factor: 32.976

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.